Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) patented
drug-delivery platform, DehydraTECH, has exhibited continued success in recent
animal lab tests by delivering cannabinoids to the bloodstream faster than
conventional cannabinoid formulations (http://ibn.fm/pYSzq). A recent article discussing the
company reads, “Lab tests and actual licensed use in the cannabis industry have
proved that DehydraTECH’s long-chain fatty acid (“LCFA”) formulation is able to
deliver cannabinoids faster than formulations with medium-chain triglyceride
(“MCT”) oils, such as coconut oil. DehydraTECH also offers the most advanced
flavor and aroma-profile masking techniques in the industry. The groundbreaking
technology could negate the need for artificial chemical masking agents or
flavoring agents/sweeteners that mask the bitter flavors and aromas of
cannabis. . . . Over the entire 60 minutes of the study, the DehydraTECH LCFA
formulation delivered a CBD blood concentration level that was 334 percent
higher than the level identified in animals that received the MCT oil
formulation. The lab tests on animals compared how quickly a DehydraTECH
formulation containing LCFA could deliver cannabinoids to the bloodstream, as
compared to a concentration-matched conventional industry cannabinoid edible
formulation with MCT oil. Coconut oil is commonly used due to its luxurious
taste and mouth-feel, which can hide unpleasant cannabis flavors.”
To view the full article, visit http://ibn.fm/kl89m
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its
disruptive delivery technology, which promotes healthier ingestion methods,
lower overall dosing and higher effectiveness of lipophilic active molecules.
Lexaria has multiple patents pending in over 40 countries around the world and
has patents granted in the United States and Australia for utilization of its
DehydraTECH delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates, more rapid delivery to the bloodstream, and
important taste-masking benefits for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment